Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;18(2):130-4.

Treating medullary thyroid carcinoma in a tertiary center. Current trends and review of the literature

Affiliations

Treating medullary thyroid carcinoma in a tertiary center. Current trends and review of the literature

E Prokopakis et al. Hippokratia. 2014 Apr.

Abstract

Objectives: We present the clinical outcome and long-term survival in patients with medullary thyroid carcinoma treated in a tertiary center. A thorough review of published series and current therapeutic approaches is also addressed.

Study design: A retrospective review.

Setting: An Academic Tertiary center.

Subjects/methods: An analysis of oncologic outcomes from 25 patients treated in our department for medullary thyroid carcinoma is performed, together with a comparison of relevant studies over the literature.

Results: The incidence of patients alive free of disease and the 5-year survival rate has been noticed to be slightly higher than the rate reported in most series.

Conclusions: Total thyroidectomy and neck dissection remains the gold standard in the treatment of medullary thyroid carcinoma. Early diagnosis and aggressive surgical treatment lead to lower rates of recurrence and invasiveness. Tyrosine-kinase inhibitor, especially vantetanib, appears to be a promising target for treatment.

Keywords: Medullary thyroid carcinoma; Tyrosine-kinase inhibitor; calcitonin; neck dissection; sporadic; thyroidectomy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Carney JA. Familial multiple endocrine neoplasia: the first 100 years. Am J Surg Pathol. 2005;29:254–274. - PubMed
    1. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363:458–460. - PubMed
    1. Wells SA, Jr, Santoro M. Targeting the RET pathway in thyroid cancer. Clin Cancer Res. 2009;15:7119–7123. - PubMed
    1. Gkountouvas A, Nikas M, Chatjimarkou F, Thomas D, Georgiadis P, Kaldrimidis P. Thyroid cancer in Greece. A tertiary center experience. J BUON. 2010;15:674–678. - PubMed
    1. Moo-Young TA, Traugott AL, Moley JF. Sporadic and familial medullary thyroid carcinoma: state of the art. Surg Clin North Am. 2009;89:1193–1204. - PMC - PubMed

LinkOut - more resources